JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

Search

Simulations Plus Inc

Abierto

SectorSanidad

14.59 4.66

Resumen

Variación precio

24h

Actual

Mínimo

13.89

Máximo

14.65

Métricas clave

By Trading Economics

Ingresos

3.9M

4.5M

Ventas

5.9M

24M

BPA

0.35

Rentabilidad por dividendo

0.48

Margen de beneficios

18.669

Empleados

212

EBITDA

4.9M

7.2M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+14.37% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.36%

Próximas Ganancias

13 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

44M

295M

Apertura anterior

9.93

Cierre anterior

14.59

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

65 / 347 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2026, 23:08 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 23:07 UTC

Ganancias

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:20 UTC

Ganancias

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 abr 2026, 23:27 UTC

Charlas de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 abr 2026, 23:22 UTC

Ganancias

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 abr 2026, 23:20 UTC

Charlas de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 abr 2026, 22:52 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:33 UTC

Ganancias

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 abr 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 abr 2026, 22:05 UTC

Ganancias

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 21:57 UTC

Ganancias

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 abr 2026, 21:55 UTC

Ganancias

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 abr 2026, 21:53 UTC

Ganancias

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

14.37% repunte

Estimación a 12 Meses

Media 16 USD  14.37%

Máximo 16 USD

Mínimo 16 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

65 / 347 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat